<p>该协议利用现有基础设施增加基于合同的收入，提高资产利用率，支持长期现金流，并通过多元化市场创造股东价值。</p>
<p>密歇根州安娜堡 / ACCESS Newswire /2026 年 1 月 22 日/ Zomedica Corp. (OTCQB:ZOMDF)（&#34;Zomedica&#34;或&#34;公司&#34;），一家为马匹和伴侣动物提供创新诊断和治疗设备的动物健康公司，今天宣布已与 Rahm Sensor Development 签署了一项合同制造和服务协议，该技术公司正在推进高风险环境下的无接触多传感器监测解决方案。</p>
<p>根据协议，Zomedica 将制造 Rahm 的首款商业产品 Cell-Guardian™，这是一种先进的人员监测设备，旨在提高高风险环境中的安全性和情境意识。Cell-Guardian™目前正在监狱和机构环境中部署，以增强安全性和情境意识。Zomedica 还将根据需要提供工程服务和一级客户服务，使 Rahm 能够加速商业化，同时利用 Zomedica 已建立的运营平台。</p>
<p>该协议将 Zomedica 的收入模式扩展到动物健康渠道之外，通过货币化现有的制造和工程能力。管理层预计，合作伙伴关系将产生额外的基于合同的收入，同时提高现有资产的利用率并限制增量固定成本。</p>
<p>Zomedica 首席执行官 Larry Heaton 表示：“该协议使我们能够通过利用我们已经拥有的资产来产生新的收入。它改善了运营杠杆，支持现金流，并与我们有序的多元化方法相一致，而不增加固定成本。我们认为这是在保持对核心动物健康业务关注的同时创造股东价值的务实方式。”</p>
<p>从投资者的角度来看，这一机会得到了相邻监测和传感器市场规模和增长的支持。根据 Grand View Research，全球可穿戴技术市场在 2024 年的估值约为 840 亿美元，预计到 2030 年将达到 1860 亿美元，反映出 13.6% 的年复合增长率。Zomedica 认为，这一市场背景支持以资本效率和执行纪律为重点的适度扩张战略。</p>
<p>Rahm Sensor Development 首席执行官 Vik Ramprakash 表示：“我们选择 Zomedica 是因为他们经验丰富的团队、成熟的质量体系以及在受监管的医疗设备环境中的运营背景。Cell-Guardian™是我们的首款商业产品，这一合作伙伴关系使我们能够加速市场进入，同时为未来的增长建立强大的制造和支持基础。”</p>
<p>随着 Rahm 产品组合的扩展，该协议提供了评估 Zomedica 参与其他项目的框架，从而为未来创造持续的制造和服务收入潜力。</p>
<p>Zomedica 业务发展和战略规划高级副总裁 Greg Blair 表示：“这一合作伙伴关系是有序多元化的明确例证。通过将我们现有的能力扩展到相邻市场，我们可以解锁更高利润的收入机会，提高资产效率，并建立可预测的基于合同的收入流。”</p>
<p>Zomedica 相信，这一合作伙伴关系将对收入增长、利润扩张和自由现金流产生积极贡献，同时增强公司作为多元化医疗技术平台的战略地位。</p>
<p><strong>关于 Zomedica</strong></p>
<p>Zomedica 是一家领先的马匹和伴侣动物健康公司，致力于通过为兽医提供创新的治疗和诊断解决方案来改善动物健康。我们的金标准 PulseVet®冲击波系统加速了肌肉骨骼疾病的愈合，改变了兽医治疗。我们的产品系列还包括 Assisi®治疗设备系列、TRUFORMA®诊断平台、TRUVIEW®数字细胞学系统、VetGuardian®零接触监测系统和 VETIGEL®止血凝胶，这是一种革命性的止血剂，能够迅速止血，所有这些都旨在帮助兽医提供顶级护理。总体而言，他们在美国的可寻址市场每年超过 20 亿美元。Zomedica 总部位于密歇根州，约有 150 名员工，并在乔治亚州和明尼苏达州的世界级设施中制造和分销其产品。Zomedica 在 2024 年实现收入增长 8%，达到 2700 万美元，并在 2025 年 9 月 30 日时保持约 5440 万美元的流动性，资产负债表稳健。Zomedica 正在推进其产品供应，利用战略收购，并在国际上扩展，以提升宠物护理质量，提高宠物家长满意度，并改善兽医实践的工作流程、现金流和盈利能力。有关更多信息，请访问 www.zomedica.com。</p>
<p><strong>关注 Zomedica</strong></p>
<ul>
<li>邮件提醒: http://investors.zomedica.com</li>
<li>LinkedIn: https://www.linkedin.com/company/zomedica</li>
<li>Facebook: https://m.facebook.com/zomedica</li>
<li>X (前身为 Twitter): https://twitter.com/zomedica</li>
<li>Instagram: https://www.instagram.com/zomedica_inc</li>
</ul>
<p>关于前瞻性声明的警示说明</p>
<p>除历史事实的陈述外，本新闻稿包含某些 “前瞻性信息” 或 “前瞻性陈述”（统称为 “前瞻性信息”），符合适用证券法的定义。前瞻性信息通常以 “计划”、“期望”、“项目”、“打算”、“相信”、“预期”、“估计” 等词语或某些事件或条件 “可能” 或 “将” 发生的陈述来表述，并包括与我们对未来结果的期望相关的陈述。尽管我们相信前瞻性信息中反映的期望是合理的，但不能保证这些期望会被证明是正确的。我们无法保证未来的结果、表现或成就。因此，实际结果与前瞻性信息中所列的结果在整体或部分上相同的陈述并不成立。</p>
<p>前瞻性信息基于管理层在陈述作出时的意见和估计，包括对经济增长、公司产品需求、公司生产和销售产品能力、预算资本和运营支出的充足性、战略合作伙伴在商业协议下履行义务的满意度以及我们实现商业计划和成本控制努力的能力的假设。</p>
<p>我们的前瞻性信息受到各种风险和不确定性以及其他因素的影响，这些因素可能导致实际事件或结果与前瞻性信息中预期的结果有重大差异。一些可能导致结果与前瞻性信息中表达的结果有重大差异的风险和其他因素包括但不限于：预期收入可能无法实现，费用可能高于预期，Rahm Sensor Development 可能选择从其他供应商处购买产品，市场上新产品采用的风险，普遍接受的会计原则的应用，这些原则高度复杂并涉及许多主观假设、估计和判断，关于我们的战略和商业计划是否会带来预期收益的不确定性；关于开发工作和验证及确认研究的时间和结果的不确定性；关于商业化努力的时间和结果的不确定性，包括国际努力，以及商业化努力的成本，包括开发内部销售团队和管理我们增长的成本；关于我们能否实现收购带来的预期增长机会的不确定性；关于我们能否根据客户需求供应产品的不确定性；与关税变化相关的供应链风险；关于任何所需监管批准的可能性和时间的不确定性，以及资本的可用性和成本；识别、开发和实现新产品和技术商业成功的能力；在采用我们的资本设备后，兽医对我们产品的接受度和对耗材的购买；来自相关产品的竞争；维持和改善产品和服务质量所需支出的水平；技术变化和法律法规变化；我们确保和维持战略关系的能力；战略合作伙伴在商业协议下履行义务的表现；与许可证和许可相关的风险、知识产权侵权风险、与任何所需临床试验和监管批准相关的风险、与我们产品的安全性和有效性、使用我们的产品、知识产权保护以及我们在 SEC 文件和 www.sedarplus.com 上的资料中披露的其他风险因素相关的风险。读者应注意，这份风险因素清单不应被视为详尽无遗。</p>
<p>本新闻稿中包含的前瞻性信息明确受到本警示声明的限制。除非适用证券法规另有要求，我们不承担更新任何前瞻性信息以使其与实际结果或我们期望的变化相符的义务。读者应谨慎对待前瞻性信息，不应过度依赖。</p>
<p><strong>投资者关系联系方式：</strong></p>
<p>Zomedica 投资者关系</p>
<p><strong>Investors@zomedica.com</strong></p>
<p>1-734-369-2555</p>
<p><strong>来源：</strong> Zomedica Corp.</p>
<p>查看 ACCESS Newswire 上的原始新闻稿</p>

美国医药设备 ETF - iShares

<p>Zomedica Corp. 与 Rahm Sensor Development 签署了一份合同制造和服务协议，以拓展其收入来源，超越动物健康领域。该协议允许 Zomedica 生产 Rahm 的 Cell-Guardian™ 人员监测设备，同时提供工程服务。此次合作旨在产生增量收入，提高资产利用率，并支持现金流，而不增加固定成本。Zomedica 预计将对收入增长和利润扩展产生积极贡献，利用其在相关市场的现有能力</p>

<p>Agreement leverages existing infrastructure to add contract-based revenue, improve asset utilization, support long-term cash flow and create shareholder value through diversified markets</p>
<div class="lb-trans"><p>该协议利用现有基础设施增加基于合同的收入，提高资产利用率，支持长期现金流，并通过多元化市场创造股东价值。</p>
</div><p>ANN ARBOR, MI / ACCESS Newswire / January 22, 2026 / Zomedica Corp. (OTCQB:ZOMDF) (&#34;Zomedica&#34; or the &#34;Company&#34;), an animal health company offering innovative diagnostic and therapeutic devices for equine and companion animals, today announced that it has entered into a contract manufacturing and service agreement with Rahm Sensor Development, a technology company advancing contact-free, multi-sensor monitoring solutions for high-risk environments.</p>
<div class="lb-trans"><p>密歇根州安娜堡 / ACCESS Newswire /2026 年 1 月 22 日/ Zomedica Corp. (OTCQB:ZOMDF)（&#34;Zomedica&#34;或&#34;公司&#34;），一家为马匹和伴侣动物提供创新诊断和治疗设备的动物健康公司，今天宣布已与 Rahm Sensor Development 签署了一项合同制造和服务协议，该技术公司正在推进高风险环境下的无接触多传感器监测解决方案。</p>
</div><p>Under the agreement, Zomedica will manufacture Rahm's first commercial product, the Cell-Guardian™, an advanced personnel monitoring device designed to improve safety and situational awareness in high-risk environments. Cell-Guardian™ is currently being deployed in correctional and institutional settings to enhance safety and situational awareness. Zomedica will also provide engineering services on an as-needed basis and Level One customer service, enabling Rahm to accelerate commercialization while leveraging Zomedica's established operational platform.</p>
<div class="lb-trans"><p>根据协议，Zomedica 将制造 Rahm 的首款商业产品 Cell-Guardian™，这是一种先进的人员监测设备，旨在提高高风险环境中的安全性和情境意识。Cell-Guardian™目前正在监狱和机构环境中部署，以增强安全性和情境意识。Zomedica 还将根据需要提供工程服务和一级客户服务，使 Rahm 能够加速商业化，同时利用 Zomedica 已建立的运营平台。</p>
</div><p>The agreement expands Zomedica's revenue model beyond the animal health channel by monetizing existing manufacturing and engineering capabilities. Management expects the partnership to generate incremental, contract-based revenue while improving utilization of existing assets and limiting incremental fixed costs.</p>
<div class="lb-trans"><p>该协议将 Zomedica 的收入模式扩展到动物健康渠道之外，通过货币化现有的制造和工程能力。管理层预计，合作伙伴关系将产生额外的基于合同的收入，同时提高现有资产的利用率并限制增量固定成本。</p>
</div><p>&#34;This agreement allows us to generate new revenue by leveraging assets we already own,&#34; said Larry Heaton, Chief Executive Officer of Zomedica. &#34;It improves operating leverage, supports cash flow, and aligns with our disciplined approach to diversification without increasing fixed costs. We view this as a practical way to create shareholder value while maintaining focus on our core animal health business.&#34;</p>
<div class="lb-trans"><p>Zomedica 首席执行官 Larry Heaton 表示：“该协议使我们能够通过利用我们已经拥有的资产来产生新的收入。它改善了运营杠杆，支持现金流，并与我们有序的多元化方法相一致，而不增加固定成本。我们认为这是在保持对核心动物健康业务关注的同时创造股东价值的务实方式。”</p>
</div><p>From an investor perspective, the opportunity is supported by the size and growth of adjacent monitoring and sensor markets. According to Grand View Research, the global wearable technology market was valued at approximately $84 billion in 2024 and is projected to reach $186 billion by 2030, reflecting a compound annual growth rate of 13.6%. Zomedica believes this market backdrop supports a measured expansion strategy focused on capital efficiency and execution discipline</p>
<div class="lb-trans"><p>从投资者的角度来看，这一机会得到了相邻监测和传感器市场规模和增长的支持。根据 Grand View Research，全球可穿戴技术市场在 2024 年的估值约为 840 亿美元，预计到 2030 年将达到 1860 亿美元，反映出 13.6% 的年复合增长率。Zomedica 认为，这一市场背景支持以资本效率和执行纪律为重点的适度扩张战略。</p>
</div><p>&#34;We chose Zomedica for their experienced team, established quality systems, and background operating in regulated medical device environments,&#34; said Vik Ramprakash, CEO of Rahm Sensor Development. &#34;Cell-Guardian™ is our first commercial product, and this partnership allows us to accelerate market entry while building a strong manufacturing and support foundation for future growth.&#34;</p>
<div class="lb-trans"><p>Rahm Sensor Development 首席执行官 Vik Ramprakash 表示：“我们选择 Zomedica 是因为他们经验丰富的团队、成熟的质量体系以及在受监管的医疗设备环境中的运营背景。Cell-Guardian™是我们的首款商业产品，这一合作伙伴关系使我们能够加速市场进入，同时为未来的增长建立强大的制造和支持基础。”</p>
</div><p>As Rahm's product portfolio expands, the agreement provides a framework to evaluate Zomedica's participation in additional programs, creating the potential for recurring manufacturing and services revenue over time.</p>
<div class="lb-trans"><p>随着 Rahm 产品组合的扩展，该协议提供了评估 Zomedica 参与其他项目的框架，从而为未来创造持续的制造和服务收入潜力。</p>
</div><p>&#34;This partnership is a clear example of disciplined diversification,&#34; said Greg Blair, Senior Vice President of Business Development and Strategic Planning at Zomedica. &#34;By extending our existing capabilities into adjacent markets, we can unlock higher-margin revenue opportunities, improve asset efficiency, and build predictable, contract-based income streams.&#34;</p>
<div class="lb-trans"><p>Zomedica 业务发展和战略规划高级副总裁 Greg Blair 表示：“这一合作伙伴关系是有序多元化的明确例证。通过将我们现有的能力扩展到相邻市场，我们可以解锁更高利润的收入机会，提高资产效率，并建立可预测的基于合同的收入流。”</p>
</div><p>Zomedica believes this partnership will contribute positively to revenue growth, margin expansion, and free cash flow over time, while strengthening the Company's strategic position as a diversified medical technology platform.</p>
<div class="lb-trans"><p>Zomedica 相信，这一合作伙伴关系将对收入增长、利润扩张和自由现金流产生积极贡献，同时增强公司作为多元化医疗技术平台的战略地位。</p>
</div><p><strong>About Zomedica</strong></p>
<div class="lb-trans"><p><strong>关于 Zomedica</strong></p>
</div><p>Zomedica is a leading equine and companion animal health company dedicated to improving animal health by providing veterinarians with innovative therapeutic and diagnostic solutions. Our gold standard PulseVet® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi® line of therapeutic devices, the TRUFORMA® diagnostic platform, the TRUVIEW® digital cytology system, the VetGuardian® Zero Touch™ monitoring system, and VETIGEL® hemostatic gel, a revolutionary hemostatic agent that rapidly stops bleeding, all designed to empower veterinarians to deliver top-tier care. In the aggregate, their total addressable market in the U.S. exceeds $2 billion annually. Headquartered in Michigan, Zomedica employs approximately 150 people and manufactures and distributes its products from its world-class facilities in Georgia and Minnesota. Zomedica grew revenue 8% in 2024 to $27 million and maintains a strong balance sheet with approximately $54.4 million in liquidity as of September 30, 2025. Zomedica is advancing its product offerings, leveraging strategic acquisitions, and expanding internationally as it works to enhance the quality of care for pets, increase pet parent satisfaction, and improve the workflow, cash flow and profitability of veterinary practices. For more information visit www.zomedica.com.</p>
<div class="lb-trans"><p>Zomedica 是一家领先的马匹和伴侣动物健康公司，致力于通过为兽医提供创新的治疗和诊断解决方案来改善动物健康。我们的金标准 PulseVet®冲击波系统加速了肌肉骨骼疾病的愈合，改变了兽医治疗。我们的产品系列还包括 Assisi®治疗设备系列、TRUFORMA®诊断平台、TRUVIEW®数字细胞学系统、VetGuardian®零接触监测系统和 VETIGEL®止血凝胶，这是一种革命性的止血剂，能够迅速止血，所有这些都旨在帮助兽医提供顶级护理。总体而言，他们在美国的可寻址市场每年超过 20 亿美元。Zomedica 总部位于密歇根州，约有 150 名员工，并在乔治亚州和明尼苏达州的世界级设施中制造和分销其产品。Zomedica 在 2024 年实现收入增长 8%，达到 2700 万美元，并在 2025 年 9 月 30 日时保持约 5440 万美元的流动性，资产负债表稳健。Zomedica 正在推进其产品供应，利用战略收购，并在国际上扩展，以提升宠物护理质量，提高宠物家长满意度，并改善兽医实践的工作流程、现金流和盈利能力。有关更多信息，请访问 www.zomedica.com。</p>
</div><p><strong>Follow Zomedica</strong></p>
<div class="lb-trans"><p><strong>关注 Zomedica</strong></p>
</div><ul>
<li>Email Alerts: http://investors.zomedica.com</li>
<li>LinkedIn: https://www.linkedin.com/company/zomedica</li>
<li>Facebook: https://m.facebook.com/zomedica</li>
<li>X (formerly Twitter): https://twitter.com/zomedica</li>
<li>Instagram: https://www.instagram.com/zomedica_inc</li>
</ul>
<div class="lb-trans"><ul>
<li>邮件提醒: http://investors.zomedica.com</li>
<li>LinkedIn: https://www.linkedin.com/company/zomedica</li>
<li>Facebook: https://m.facebook.com/zomedica</li>
<li>X (前身为 Twitter): https://twitter.com/zomedica</li>
<li>Instagram: https://www.instagram.com/zomedica_inc</li>
</ul>
</div><p>Cautionary Note Regarding Forward-Looking Statements</p>
<div class="lb-trans"><p>关于前瞻性声明的警示说明</p>
</div><p>Except for statements of historical fact, this news release contains certain &#34;forward-looking information&#34; or &#34;forward-looking statements&#34; (collectively, &#34;forward-looking information&#34;) within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as &#34;plan&#34;, &#34;expect&#34;, &#34;project&#34;, &#34;intend&#34;, &#34;believe&#34;, &#34;anticipate&#34;, &#34;estimate&#34; and other similar words, or statements that certain events or conditions &#34;may&#34; or &#34;will&#34; occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.</p>
<div class="lb-trans"><p>除历史事实的陈述外，本新闻稿包含某些 “前瞻性信息” 或 “前瞻性陈述”（统称为 “前瞻性信息”），符合适用证券法的定义。前瞻性信息通常以 “计划”、“期望”、“项目”、“打算”、“相信”、“预期”、“估计” 等词语或某些事件或条件 “可能” 或 “将” 发生的陈述来表述，并包括与我们对未来结果的期望相关的陈述。尽管我们相信前瞻性信息中反映的期望是合理的，但不能保证这些期望会被证明是正确的。我们无法保证未来的结果、表现或成就。因此，实际结果与前瞻性信息中所列的结果在整体或部分上相同的陈述并不成立。</p>
</div><p>Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements and our ability to realize upon our business plans and cost control efforts.</p>
<div class="lb-trans"><p>前瞻性信息基于管理层在陈述作出时的意见和估计，包括对经济增长、公司产品需求、公司生产和销售产品能力、预算资本和运营支出的充足性、战略合作伙伴在商业协议下履行义务的满意度以及我们实现商业计划和成本控制努力的能力的假设。</p>
</div><p>Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the expected revenue may not materialize, the expenses may be greater than anticipated, Rahm Sensor Development may elect to purchase products from another vendor, the risks associated with the adoption of new products in the marketplace, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, including international efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to realize the anticipated growth opportunities from our acquisitions; uncertainty as to our ability to supply products in response to customer demand; supply chain risks associated with tariff changes; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products and purchase of consumables following adoption of our capital equipment; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at www.sedarplus.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.</p>
<div class="lb-trans"><p>我们的前瞻性信息受到各种风险和不确定性以及其他因素的影响，这些因素可能导致实际事件或结果与前瞻性信息中预期的结果有重大差异。一些可能导致结果与前瞻性信息中表达的结果有重大差异的风险和其他因素包括但不限于：预期收入可能无法实现，费用可能高于预期，Rahm Sensor Development 可能选择从其他供应商处购买产品，市场上新产品采用的风险，普遍接受的会计原则的应用，这些原则高度复杂并涉及许多主观假设、估计和判断，关于我们的战略和商业计划是否会带来预期收益的不确定性；关于开发工作和验证及确认研究的时间和结果的不确定性；关于商业化努力的时间和结果的不确定性，包括国际努力，以及商业化努力的成本，包括开发内部销售团队和管理我们增长的成本；关于我们能否实现收购带来的预期增长机会的不确定性；关于我们能否根据客户需求供应产品的不确定性；与关税变化相关的供应链风险；关于任何所需监管批准的可能性和时间的不确定性，以及资本的可用性和成本；识别、开发和实现新产品和技术商业成功的能力；在采用我们的资本设备后，兽医对我们产品的接受度和对耗材的购买；来自相关产品的竞争；维持和改善产品和服务质量所需支出的水平；技术变化和法律法规变化；我们确保和维持战略关系的能力；战略合作伙伴在商业协议下履行义务的表现；与许可证和许可相关的风险、知识产权侵权风险、与任何所需临床试验和监管批准相关的风险、与我们产品的安全性和有效性、使用我们的产品、知识产权保护以及我们在 SEC 文件和 www.sedarplus.com 上的资料中披露的其他风险因素相关的风险。读者应注意，这份风险因素清单不应被视为详尽无遗。</p>
</div><p>The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.</p>
<div class="lb-trans"><p>本新闻稿中包含的前瞻性信息明确受到本警示声明的限制。除非适用证券法规另有要求，我们不承担更新任何前瞻性信息以使其与实际结果或我们期望的变化相符的义务。读者应谨慎对待前瞻性信息，不应过度依赖。</p>
</div><p><strong>Investor Relations Contact:</strong></p>
<div class="lb-trans"><p><strong>投资者关系联系方式：</strong></p>
</div><p>Zomedica Investor Relations</p>
<div class="lb-trans"><p>Zomedica 投资者关系</p>
</div><p><strong>Investors@zomedica.com</strong></p>
<div class="lb-trans"><p><strong>Investors@zomedica.com</strong></p>
</div><p>1-734-369-2555</p>
<div class="lb-trans"><p>1-734-369-2555</p>
</div><p><strong>SOURCE:</strong> Zomedica Corp.</p>
<div class="lb-trans"><p><strong>来源：</strong> Zomedica Corp.</p>
</div><p>View the original press release on ACCESS Newswire</p>
<div class="lb-trans"><p>查看 ACCESS Newswire 上的原始新闻稿</p>
</div>

Zomedica 与 Rahm Sensor Development 签订合同制造和服务协议，旨在拓展除动物健康之外的收入来源